← Back to Search

Behavioral Intervention

MAAT-G for Cognitive Impairment

N/A

Waitlist Available

Led By Allison Magnuson

Research Sponsored by University of Rochester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up post-intervention (up to 2 weeks)

Awards & highlights

Study Summary

This trial will test a promising new treatment for cancer-related cognitive dysfunction in older adults.

Eligible Conditions

Cognitive Impairment
Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ post-intervention (up to 2 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~post-intervention (up to 2 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and post-intervention (up to 2 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Experience Interview

System Usability Scale (SUS)

Secondary outcome measures

Cambridge Neuropsychological Test Automated Battery (CANTAB)

Controlled Oral Word Association (COWA)

Functional Assessment of Cancer Therapy-Cognition (FACT-COG)

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: MAAT-G InterventionExperimental Treatment1 Intervention

MAAT-G Workshops & participant workbook use (8 workshops)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MAAT-G

2020

N/A

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH

1,668 Previous Clinical Trials

28,005,060 Total Patients Enrolled

University of RochesterLead Sponsor

836 Previous Clinical Trials

518,164 Total Patients Enrolled

Allison MagnusonPrincipal InvestigatorUniversity of Rochester

2 Previous Clinical Trials

340 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the ultimate goal of this research endeavor?

"This trial's primary outcome, assessed up to two weeks post-intervention, is measured using the System Usability Scale. Secondly, Generalized Anxiety and Depression 7-item scale (GAD-7), Cambridge Neuropsychological Test Automated Battery (CANTAB) and Controlled Oral Word Association (COWA) are being used to gauge health outcomes; GAD-7 evaluates feelings of anxiety over two weeks with higher scores suggesting worse results; CANTAB assesses simultaneous visual matching ability as well as short term recognition memory, while COWA gauges verbal fluency in terms of expressive language and executive function by asking participants"

Answered by AI

Are there vacancies for people to partake in this research?

"According to clinicaltrials.gov, this trial is still open for recruitment and has been since its inception on June 12th 2020 with its last edit occurring on January 14th 2022."

Answered by AI

What is the total participant count of this clinical trial?

"Yes, the clinicaltrials.gov database indicates that recruitment for this trial is in progress. The study was initially posted on June 12th 2020 and has been most recently updated January 14th 2022. 39 patients are being sought from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Memory and Attention Adaptation Training-Geriatrics (MAAT-G)

Allison Magnuson 2020. "Memory and Attention Adaptation Training-Geriatrics (MAAT-G)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04230941.